2 Fantastic Dividend Stocks to Buy and Hold Forever

Abbott Laboratories and Medtronic are presented as resilient, dividend-growing med‑tech leaders well suited for income-focused portfolios, each generating steady revenue and profits. Abbott benefits from pricing power and life‑critical products, with its FreeStyle Libre continuous glucose monitor — the top medical device by dollar sales — providing a major growth tailwind and supporting a 53‑year streak of dividend increases. Medtronic is repositioning to boost margins by exiting its uncompetitive diabetes unit and is pursuing longer‑term growth from its Hugo robotic surgical system that is nearing regulatory clearance, while maintaining 48 consecutive years of payout increases. The article includes disclosures that The Motley Fool holds positions in and recommends some of the mentioned names.

Analysis

The article frames Abbott Laboratories (ABT) and Medtronic (MDT) as resilient, dividend-focused medical-device leaders with attractive long-term prospects. Abbott is highlighted for pricing power and life-or-death product demand, with its FreeStyle Libre continuous glucose monitor described as the top medical device in history by dollar sales and a key growth driver supporting a 53-year consecutive dividend increase.

Medtronic is presented as improving its margin profile by discontinuing its underperforming diabetes care unit — a response to competitive pressure from leaders like Abbott — while pursuing long-term upside from the Hugo robotic-assisted surgery system that is nearing regulatory clearance and could compete with Intuitive Surgical. The company also maintains a 48-year dividend growth streak, but the article flags tariff exposure to Medtronic’s global business and the need for regulatory and commercial execution on Hugo.

Market context and source disclosure matter: the sentiment signal is moderately positive, but The Motley Fool discloses positions in and recommendations for the names and options on MDT, and ABT was not included in its advertised top-10 list, indicating potential selection bias. These companies fit income-oriented portfolios, yet key execution, regulatory, competitive, and macro risks warrant close monitoring before scaling positions.

Key Decisions for Investors

• Consider modestly increasing exposure to Abbott (ABT) for dividend reliability and FreeStyle Libre secular growth, while sizing positions to limit concentration risk in a single franchise
• Treat Medtronic (MDT) as a buy-on-weakness opportunity given potential margin improvement from exiting diabetes and upside if Hugo earns approvals, but keep positions limited until regulatory clearance and early commercial traction are confirmed
• Monitor three near-term indicators before allocating more capital: international CGM penetration and Libre sales trends, the regulatory timeline and initial market performance of Hugo, and any tariff-driven margin pressure on Medtronic
• Account for potential source bias—Motley Fool disclosures show positions and option trades in these names—so validate thesis with independent financials, analyst models, and primary regulatory updates before making sizable allocations